Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator Driven Observational Study to Determine the Benefit of Octagam 5% for Treatment of Patients Diagnosed With Primary Immunodeficiency Disorders (PID) on Intravenous Immunoglobulin (IVIG) Therapy That Experience Adverse Events (AEs) on Any 10% IVIG Preparation

NCT03339778 is registered in ClinicalTrials.gov with IMMUNOe Research Centers as lead sponsor.

NCT NCT03339778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03339778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator Driven Observational Study to Determine the Benefit of Octagam 5% for Treatment of Patients Diagnosed With Primary Immunodeficiency Disorders (PID) on Intravenous Immunoglobulin (IVIG) Therapy That Experience Adverse Events (AEs) on Any 10% IVIG Preparation
Lead sponsor
IMMUNOe Research Centers
Phase
Observational
Overall status
Completed
Start date
June 30, 2015
Completion date
September 30, 2017
Enrollment
15 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency